All-cause and cause-specific mortality assessment in patients receiving sodium glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials - PubMed
7 hours ago
- #SGLT2 inhibitors
- #cardiorenal outcomes
- #mortality meta-analysis
- SGLT2 inhibitors did not significantly reduce overall all-cause mortality compared to control (RR: 0.92).
- A significant reduction in all-cause mortality was observed in older adults (>65 years).
- Non-cardiovascular mortality was neutral overall but reduced in younger participants (<65 years).
- SGLT2i use was associated with significant reductions in cardiovascular mortality (RR: 0.86) and renal mortality (RR: 0.31).
- The meta-analysis included 18 RCTs with 95,913 patients.
- Findings suggest SGLT2i are a cornerstone cardiorenal therapy, with implications for personalized treatment across ages.